Nominal and free antiarrhythmic concentrations
| Antiarrhythmic | Clinical plasma concentrations (µM) | LogPa | mmb | ||
| Experimental concentrations (µM) | |||||
| Nominal | Free | ||||
| Dronedarone | 0.15–0.3c | 10 | 7 × 10−5 | 8.75 | 4.0 × 10−2 |
| Amiodarone | 1d | 30 | 1 × 10−3 | 7.8 | 10−1 |
| Propranolol | 0.01–1e | 200 | 90 | 3.48 | 2.5 × 10−1 |
| Pindolol | 0.04f | 300 | 300 | 1.75 | 1.5 × 10−2 |
| Antiarrhythmic | Clinical plasma concentrations (µM) | LogPa | mmb | ||
| Experimental concentrations (µM) | |||||
| Nominal | Free | ||||
| Dronedarone | 0.15–0.3c | 10 | 7 × 10−5 | 8.75 | 4.0 × 10−2 |
| Amiodarone | 1d | 30 | 1 × 10−3 | 7.8 | 10−1 |
| Propranolol | 0.01–1e | 200 | 90 | 3.48 | 2.5 × 10−1 |
| Pindolol | 0.04f | 300 | 300 | 1.75 | 1.5 × 10−2 |
Benet et al. (2011).
Estimated following Bruno et al. (2007), Ingólfsson et al. (2007), and Rusinova et al. (2011).
Heijman et al. (2013a).
Haffajee et al. (1983), Latini et al. (1984), and Seydel (2003).
Woosley et al. (1979), Wilson et al. (1982), and Seydel (2003).
Channer et al. (1994) and Mehvar and Brocks (2001).